BICO Group AB Class B ( (CLLKF) ) has released its Q1 earnings. Here is a breakdown of the information BICO Group AB Class B presented to its investors.
BICO Group AB is a company specializing in bioprinting and lab automation solutions, operating within the life sciences sector, known for its innovative technologies in 3D bioprinting and lab automation software.
In its latest earnings report for the first quarter of 2025, BICO Group AB reported a decline in net sales by 17.3% compared to the same period last year, with net sales amounting to SEK 388.6 million. Despite the decrease in sales, the company achieved a gross margin of 54%, an improvement from the previous year’s 44.5%.
The report highlighted a significant decline in the Lab Automation segment, which experienced a 58% drop in organic growth due to fewer project starts and closures. However, the Bioprinting segment showed a robust organic growth of 41%, driven by successful turnaround activities in CELLINK. The company also announced the divestment of MatTek and Visikol to Sartorius for USD 80 million, aligning with its strategic focus on lab automation and selected workflows.
Looking ahead, BICO Group AB remains focused on its updated strategy, BICO 2.0, which emphasizes commercial and operational excellence, and aims to strengthen its position in lab automation and life science solutions. The management expects to achieve a positive net cash position in the second quarter of 2025, following the divestment and continued efforts to optimize its capital structure.